Preclinical and clinical effects of mistletoe against breast cancer
- PMID: 25136622
- PMCID: PMC4127267
- DOI: 10.1155/2014/785479
Preclinical and clinical effects of mistletoe against breast cancer
Abstract
Breast cancer is among the most frequent types of cancer in women worldwide. Current conventional treatment options are accompanied by side effects. Mistletoe is amongst the important herbal medicines traditionally used as complementary remedies. An increasing number of studies have reported anticancer activity of mistletoe extracts on breast cancer cells and animal models. Some recent evidence suggests that cytotoxic activity of mistletoe may be mediated through different mechanisms. These findings provide a good base for clinical trials. Various studies on mistletoe therapy for breast cancer patients revealed similar findings concerning possible benefits on survival time, health-related quality of life (HRQoL), remission rate, and alleviating adverse reactions to conventional therapy. This review provides an overview of the recent findings on preclinical experiments and clinical trials of mistletoe for its cytotoxic and antitumor activity and its effect on HRQoL in breast cancer patients. Moreover, studies investigating molecular and cellular mechanisms underlying antitumor activity of mistletoe are discussed in this paper. The analyzed trials provided evidence that there might be a combination of pharmacological and motivational aspects mediated by the mistletoe extract application which may contribute to the clinical benefit and positive outcome such as improved HRQoL and self-regulation in breast cancer patients.
Figures
Similar articles
-
Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.Anticancer Res. 2004 Jan-Feb;24(1):303-9. Anticancer Res. 2004. PMID: 15015612 Clinical Trial.
-
[Favourable course of persisting malignant ascites].Forsch Komplementmed. 2009 Feb;16(1):49-53. doi: 10.1159/000191067. Epub 2009 Jan 30. Forsch Komplementmed. 2009. PMID: 19295230 German.
-
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).Forsch Komplementmed. 2006 Oct;13(5):285-92. doi: 10.1159/000095378. Epub 2006 Oct 20. Forsch Komplementmed. 2006. PMID: 17057389 Clinical Trial.
-
Patient' and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment.Eur J Oncol Nurs. 2023 Aug;65:102338. doi: 10.1016/j.ejon.2023.102338. Epub 2023 May 7. Eur J Oncol Nurs. 2023. PMID: 37321128
-
[Mistletoe in the treatment of cancer patients].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 May;63(5):535-540. doi: 10.1007/s00103-020-03122-x. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 32211937 Review. German.
Cited by
-
Phytochemical Profile and Antioxidant Capacity of Viscum album L. Subsp. album and Effects on Its Host Trees.Plants (Basel). 2022 Nov 9;11(22):3021. doi: 10.3390/plants11223021. Plants (Basel). 2022. PMID: 36432750 Free PMC article.
-
Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.Sci Rep. 2019 Apr 23;9(1):6428. doi: 10.1038/s41598-019-41444-2. Sci Rep. 2019. PMID: 31015523 Free PMC article.
-
Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity.Cancers (Basel). 2022 Oct 23;14(21):5203. doi: 10.3390/cancers14215203. Cancers (Basel). 2022. PMID: 36358622 Free PMC article.
-
In-Vitro Growth Kinetics of Mesenchymal Stem Cells in Cytotoxicity Tests Using Low-Diluted Viscum Album.Homeopathy. 2023 Feb;112(1):40-49. doi: 10.1055/s-0042-1747682. Epub 2022 Aug 21. Homeopathy. 2023. PMID: 35988582 Free PMC article.
-
Distinct Modulatory Effects of Fever-Range Hyperthermia on the Response of Breast Cancer Cells and Macrophages to Mistletoe (Viscum album L.) Extract.Pharmaceuticals (Basel). 2021 Jun 8;14(6):551. doi: 10.3390/ph14060551. Pharmaceuticals (Basel). 2021. PMID: 34201348 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: IARC cancer base. GLOBOCAN 2012. 2013;1(11)
-
- American Cancer Society. Global Cancer Facts & Figures. 2nd edition. Atlanta, Ga, USA: American Cancer Society; 2011.
-
- Jemal A, Bray F, Ferlay J. Global cancer statistics. CA Cancer Journal for Clinicians. 2011;61(2):69–90. - PubMed
-
- SEER stat fa ct sheets: breast cancer. 2011, http://seer.cancer.gov/statfacts/html/breast.html.
-
- Prosnitz J, Iglehart RR, Winer E. Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. New York, NY, USA: Saunders; 2001. Breast cancer; pp. 267–299.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical